The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial
Open accessAbstract
In the STEP-HFpEF trial, semaglutide improved symptoms, physical limitations and exercise function and reduced body weight in patients with obesity phenotype of heart failure and preserved ejection fraction (HFpEF). This prespecified analysis examined the effects of semaglutide on dual primary endpoints (change in Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS) and body weight) and confirmatory secondary endpoints (change in 6-minute walk distance (6MWD), hierarchical composite (death, HF events, change in KCCQ-CSS and 6MWD) and change in C-reactive protein (CRP)) across obesity classes I–III (body mass index (BMI) 30.0–34.9 kg m − 2 , 35.0–39.9 kg m − 2 and ≥40 kg m − 2 ) and according to body weight reduction with semaglutide after 52 weeks. Semaglutide consistently improved all outcomes across obesity categories ( P value for treatment effects × BMI interactions = not significant for all). In semaglutide-treated patients, improvements in KCCQ-CSS, 6MWD and CRP were greater with larger body weight reduction (for example, 6.4-point (95% confidence interval (CI): 4.1, 8.8) and 14.4-m (95% CI: 5.5, 23.3) improvements in KCCQ-CSS and 6MWD for each 10% body weight reduction). In participants with obesity phenotype of HFpEF, semaglutide improved symptoms, physical limitations and exercise function and reduced inflammation and body weight across obesity categories. In semaglutide-treated patients, the magnitude of benefit was directly related to the extent of weight loss. Collectively, these data support semaglutide-mediated weight loss as a key treatment strategy in patients with obesity phenotype of HFpEF. ClinicalTrials.gov identifier: NCT04788511 .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“All AOMs that are FDA-approved for long-term use reduce weight on average by ≥5% more than placebo after 1y; the proportion achieving weight loss ≥5% is also significantly greater than that achieved by the placebo group; several also prevent progression of prediabetes to diabetes and improve quality of life (QoL).[79][80][81]”
From Approach to Obesity Treatment in Primary Care: A Review (2024) · cites this paper as [79]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Obokata, M., Reddy, Y. N. V., Pislaru, S. V., Melenovsky, V., & Borlaug, B. A. (2017) · Circulation · doi:10.1161/circulationaha.116.026807 · Cited by 1,179
Self-citationKitzman, D. W., Brubaker, P., Morgan, T., Haykowsky, M., Hundley, G., Kraus, W. E., Eggebeen, J., & Nicklas, B. J. (2016) · JAMA · doi:10.1001/jama.2015.17346 · Cited by 921
Self-citationHeart Failure With Preserved Ejection Fraction
Borlaug, B. A., Sharma, K., Shah, S. J., & Ho, J. E. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.01.049 · Cited by 742
Self-citationHeart Failure With Preserved Ejection Fraction: A Review
Redfield, M. M., & Borlaug, B. A. (2023) · JAMA · doi:10.1001/jama.2023.2020 · Cited by 662
Self-citationBorlaug, B. A., Jensen, M. D., Kitzman, D. W., Lam, C. S. P., Obokata, M., & Rider, O. J. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvac120 · Cited by 450
Self-citationReddy, Y. N. V., Rikhi, A., Obokata, M., Shah, S. J., Lewis, G. D., AbouEzzedine, O. F., Dunlay, S., McNulty, S., Chakraborty, H., Stevenson, L. W., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1788 · Cited by 243
Self-citationKitzman, D. W., & Shah, S. J. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.05.019 · Cited by 194
Self-citationSorimachi, H., Obokata, M., Takahashi, N., Reddy, Y. N. V., Jain, C. C., Verbrugge, F. H., Koepp, K. E., Khosla, S., Jensen, M. D., & Borlaug, B. A. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa823 · Cited by 183
Self-citationDapagliflozin for heart failure according to body mass index: the DELIVER trial
Adamson, C., Kondo, T., Jhund, P. S., de Boer, R. A., Honorio, J. W. C., Claggett, B. L., Desai, A. S., Gamba, M. A. A., Habeeb, W. A., Hernandez, A. F., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac481 · Cited by 165
Self-citationHemodynamic Effects of Weight Loss in Obesity
Reddy, Y. N. V., Narayanan, M. A., Obokata, M., Koepp, K. E., Erwin, P. J., Carter, R. E., & Borlaug, B. A. (2019) · JACC Heart Failure · doi:10.1016/j.jchf.2019.04.019 · Cited by 153
Self-citation
Research works printed but not linked: 1
- Kosiborod, M. N. et al. Once weekly semaglutide in heart failure with preserved ejection fraction and obesity. N. Engl. J. Med. (in the press).
Cited by
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker, D. J. (2024) · Diabetes Care · doi:10.2337/dci24-0003 · Cited by 383
Diabetes mellitus—Progress and opportunities in the evolving epidemic
Abel, E. D., Gloyn, A. L., Evans-Molina, C., Joseph, J. J., Misra, S., Pajvani, U. B., Simcox, J., Susztak, K., & Drucker, D. J. (2024) · Cell · doi:10.1016/j.cell.2024.06.029 · Cited by 292
Kosiborod, M. N., Deanfield, J., Pratley, R., Borlaug, B. A., Butler, J., Davies, M. J., Emerson, S. S., Kahn, S. E., Kitzman, D. W., Lingvay, I., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01643-x · Cited by 308
Self-citationObesity and cardiovascular disease: An ESC clinical consensus statement
Koskinas, K. C., Van Craenenbroeck, E. M., Antoniades, C., Blüher, M., Gorter, T. M., Hanssen, H., Marx, N., McDonagh, T. A., Mingrone, G., Rosengren, A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae508 · Cited by 313
The Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction
Packer, M. (2025) · JACC · doi:10.1016/j.jacc.2025.06.055 · Cited by 173
Metadata
- Authors
- Borlaug, B. A., Kitzman, D. W., Davies, M. J., Rasmussen, S., Barros, E., Butler, J., Einfeldt, M. N., Hovingh, G. K., Møller, D. V., Petrie, M. C., Shah, S. J., Verma, S., Abhayaratna, W., Ahmed, F. Z., Chopra, V., Ezekowitz, J., Fu, M., Ito, H., Lelonek, M., Melenovsky, V., Núñez, J., Perna, E., Schou, M., Senni, M., van der Meer, P., Von Lewinski, D., Wolf, D., & Kosiborod, M. N.
- Affiliations
- Mayo Clinic (US)
- Wake Forest University Health Sciences (US)
- University of Leicester (GB)
- Novo Nordisk (Denmark) (DK)
- University of Mississippi (US)
- University of Glasgow (GB)
- Northwestern University (US)
- St. Michael's Hospital (CA)
- Australian National University (AU)
- University of Manchester (GB)
- Max Super Speciality Hospital (IN)
- University of Alberta (CA)
- Sahlgrenska University Hospital (SE)
- Kawasaki Medical School (JP)
- Medical University of Lodz (PL)
- Universitat de València (ES)
- University of Copenhagen (DK)
- Ospedale Papa Giovanni XXIII (IT)
- University Medical Center Groningen (NL)
- Medical University of Graz (AT)
- University of Freiburg (DE)
- Saint Luke's Hospital (US)
- Corresponding author
- Kosiborod, Mikhail N.
- ORCID
- Borlaug, Barry A.
- Kitzman, Dalane W.
- Davies, Melanie J.
- Barros, Eric
- Butler, Javed
- Einfeldt, Mette Nygaard
- Hovingh, G. Kees
- Petrie, Mark C.
- Shah, Sanjiv J.
- Verma, Subodh
- Abhayaratna, Walter
- Ahmed, Fozia Z.
- Chopra, Vijay
- Ezekowitz, Justin
- Fu, Michael
- Ito, Hiroshi
- Lelonek, Małgorzata
- Núñez, Julio
- Perna, Eduardo
- Schou, Morten
- Senni, Michele
- van der Meer, Peter
- Von Lewinski, Dirk
- Wolf, Dennis
- Kosiborod, Mikhail N.
- Venue
- Nature Medicine
- Published
- 2023-08-27
- Volume
- 29
- Issue
- 9
- Pages
- 2358-2365
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC10504076
- OpenAlex
- W4386203424
- Cited by
- 215
- References
- 16
- Citations by year
- 2026: 44 · 2025: 72 · 2024: 89 · 2023: 10
- FWCI
- 42.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion, cc-by)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by)
- BOA (University of Milano-Bicocca) (submittedVersion, cc-by)
- Figshare (submittedVersion, cc-by)
- Pure Amsterdam UMC (submittedVersion, cc-by)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
- Greater South Information System
- Funders
- U.S. Department of Defense (W81XWH2210245)
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company (R01 HL128526, R01 HL162828, U01 HL160226)
- Pfizer
- AstraZeneca (RE/18/6/34217)
- GlaxoSmithKline
- Sanofi
- Heart and Stroke Foundation of Canada
- Gilead Sciences
- Alnylam Pharmaceuticals
- Edwards Lifesciences
- Northwestern University
- United Therapeutics Corporation (R01 HL127028, R01 HL140731, R01 HL107577)
- University of Missouri
- Boston Scientific Corporation
- University of Missouri-Kansas City
- Regeneron Pharmaceuticals
- LivaNova
- Amarin Corporation
- Cytokinetics
- Prothena
- MyoKardia
- Saint Luke's Health System
- NGM Biopharmaceuticals
- Impulse Dynamics
- University of Alberta
- National Institute for Health and Care Research
- British Heart Foundation (18/6/34217, RE/18/6/34217, RE/13/5/30177)
- University of Glasgow
- Australian National University
- Deutsche Forschungsgemeinschaft (SFB 1425)
- Rijksuniversiteit Groningen
- Albert-Ludwigs-Universität Freiburg
- Gentofte Hospital
- Daiichi-Sankyo
- Gedeon Richter
- University of Toronto
- Novo Nordisk (NCT04788511)
- Universitair Medisch Centrum Groningen
- Uniwersytet Łódzki
- Sahlgrenska Universitetssjukhuset
- Karl-Franzens-Universität Graz
- Kawasaki Medical School
- Medizinische Universität Graz
- Servier
- Sun Pharma
- INCLIVA Instituto de Investigación Sanitaria
- HLS Therapeutics
- National Institutes of Health (W81XWH2210245, SFB1425, UL1TR001873, UL1TR002384)
- Feinberg School of Medicine
- American Regent
- Canadian Institutes of Health Research
- Medizinische Fakultät der Albert-Ludwigs-Universität Freiburg
- National Institute on Aging (U01AG076928, R01AG018915, R01AG045551, P30AG021332, U24AG059624, R01AG078153)
- National Heart, Lung, and Blood Institute (R01HL128526, R01HL127028, R01HL149423, R01HL140731, R01HL107577, U01HL160226, U54HL160273, R01HL162828, U01HL160272)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- semaglutide, heart failure with preserved ejection fraction, obesity phenotypes, weight loss, obesity class, Kansas City Cardiomyopathy Questionnaire, 6-minute walk distance, C-reactive protein, inflammation, GLP-1 receptor agonists
- MeSH terms
- Semaglutide, Body Weight, C-Reactive Protein, Heart Failure, Humans, Obesity, Stroke Volume, Weight Loss
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial. https://app.cochat.ai/papers/10.1038/s41591-023-02526-x
- The paper
- Borlaug, B. A., Kitzman, D. W., Davies, M. J., Rasmussen, S., Barros, E., Butler, J., Einfeldt, M. N., Hovingh, G. K., Møller, D. V., Petrie, M. C., Shah, S. J., Verma, S., Abhayaratna, W., Ahmed, F. Z., Chopra, V., Ezekowitz, J., Fu, M., Ito, H., Lelonek, M., . . . Kosiborod, M. N. (2023). Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial. Nature Medicine. https://doi.org/10.1038/s41591-023-02526-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.